Program
plecanatide
Also written as “Plecanatide”, “SP-304 0.3 mg” and “SP-304 1.0 mg”.
Its studies are mostly in Constipation · Irritable Bowel Syndrome · Bronchiolitis Obliterans Syndrome, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bausch Health Companies | 121 open or running | phase 3since Sep 6, 2011 | Jan 12, 2010 | Oct 18, 2027phase 2 · NCT07723924 |
| Shandong Luoxin Pharmaceutical Group Stock | 10 open or running | phase 3since Nov 4, 2021 | Nov 4, 2021 | none ahead |
Also a collaborator on its studies: parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 12, 2010First study: phase 2 study in ConstipationNew to Bausch Health CompaniesBausch Health Companies · NCT01053962 · 84 enrolled · United States
- Sep 6, 2011Phase 3 study in ConstipationBausch Health Companies · NCT01429987 · 951 enrolled · United States
- Nov 2, 2012Phase 2 study in Irritable Bowel Syndrome Characterized by ConstipationBausch Health Companies · NCT01722318 · 428 enrolled · United States
- Aug 7, 2013Phase 3 study in Bronchiolitis Obliterans SyndromeBausch Health Companies · NCT01919697 · 2,370 enrolled · United States, Canada
- Nov 5, 2013Phase 3 study in ConstipationBausch Health Companies · NCT01982240 · 1,394 enrolled · United States, Canada
- Apr 22, 2014Phase 3 study in ConstipationBausch Health Companies · NCT02122471 · 1,410 enrolled · United States
- Jan 20, 2015Phase 3 study in Irritable Bowel Syndrome Characterized by ConstipationBausch Health Companies · NCT02387359 · 1,054 enrolled · United States
- Jun 23, 2015Phase 3 study in Irritable Bowel Syndrome Characterized by ConstipationBausch Health Companies · NCT02493452 · 1,135 enrolled · United States
- Feb 29, 2016Phase 3 study in Irritable Bowel SyndromeBausch Health Companies · NCT02706483 · 2,272 enrolled · United States
- Apr 18, 2017Phase 2 study in Chronic Idiopathic ConstipationBausch Health Companies · NCT03120520 · 124 enrolled · United States
- Jul 12, 2018Phase 2 study in Irritable Bowel Syndrome With ConstipationBausch Health Companies · NCT03596905 · 218 enrolled · United States
- Nov 4, 2021Shandong Luoxin Pharmaceutical Group Stock's first study: phase 3 study in Functional ConstipationNew to Shandong Luoxin Pharmaceutical Group StockShandong Luoxin Pharmaceutical Group Stock · NCT05151328 · 648 enrolled · China
- Jul 20, 2026Phase 2 study in ConstipationBausch Health Companies · NCT07723924 · 180 enrolled · United States
Ahead
- Oct 18, 2027Primary completion: phase 2 study in ConstipationBausch Health Companies · NCT07723924
TargetBeta
“An agonist of intestinal guanylate cyclase type C (GC-C) which is almost structurally identical to human uroguanylin, with laxative and anti-nociceptive activities”NCIt, by rule
“Heat-stable enterotoxin receptor agonist”ChEMBL 37, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07723924Constipation · United States | 2 | Active, not recruiting | Bausch Health Companies | Oct 18, 2027 | 180 |
| NCT05151328Functional Constipation · China | 3 | Completed | Shandong Luoxin Pharmaceutical Group Stock | Oct 12, 2023 | 648 |
| NCT03596905Irritable Bowel Syndrome With Constipation · United States | 2 | Completed | Bausch Health Companies | Nov 25, 2024 | 218 |
| NCT03120520Chronic Idiopathic Constipation · United States | 2 | Completed | Bausch Health Companies | Sep 7, 2018 | 124 |
| NCT02706483Irritable Bowel Syndrome · United States | 3 | Completed | Bausch Health Companies | May 2017 | 2,272 |
| NCT02493452Irritable Bowel Syndrome Characterized by Constipation · United States | 3 | Completed | Bausch Health Companies | Nov 2016 | 1,135 |
| NCT02387359Irritable Bowel Syndrome Characterized by Constipation · United States | 3 | Completed | Bausch Health Companies | Dec 2016 | 1,054 |
| NCT02122471Constipation · United States | 3 | Completed | Bausch Health Companies | May 2015 | 1,410 |
| NCT01982240Constipation · United States, Canada | 3 | Completed | Bausch Health Companies | Apr 2015 | 1,394 |
| NCT01919697Bronchiolitis Obliterans Syndrome · United States, Canada | 3 | Completed | Bausch Health Companies | Jan 2016 | 2,370 |
| NCT01722318Irritable Bowel Syndrome Characterized by Constipation · United States | 2 | Completed | Bausch Health Companies | Apr 2014 | 428 |
| NCT01429987Constipation · United States | 3 | Completed | Bausch Health Companies | Dec 2012 | 951 |
| NCT01053962Constipation · United States | 2 | Completed | Bausch Health Companies | Aug 2010 | 84 |
How it is read
Names in the registry
- “Plecanatide”, 10 entries
- “plecanatide”, 2 entries
- “SP-304 0.3 mg”, 1 entry
- “SP-304 1.0 mg”, 1 entry
- “SP-304 3.0 mg”, 1 entry
Conditions, from the studies’ own filings
- Constipation, 11 studies
- Irritable Bowel Syndrome, 1 study
- Bronchiolitis Obliterans Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.